Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Bao Oanh Nguyen
Bao-Oanh Nguyen attended medical school at the University of Maastricht. During her Master of Medicine she engaged in clinical research at the department of cardiology. She received her Doctor of Medicine degree in 2016 and gained experience as a clinical doctor at the cardiology department. Since 2017 she started a PhD in cardiology under the supervision of professor Isabelle van Gelder and… View more
AHA 22 Late-Breaker Discussion: The DCP Trial
Author(s): Areef Ishani , Harriette Van Spall Added: 1 year ago
AHA 2022 — Late-breaker Host, Dr Harriette Van Spall (McMaster University, CA) met investigator, Dr Areef Ishani (Minneapolis VA Health Care System, US)to discuss the The Diuretic Comparison Project (DCP) (NCT02185417). The aim of this study was to compare two thiazide-type diuretics, chlorthalidone and hydrochlorothiazide in 13523 patients over age 65 with hypertension. Published in The New… View more

Prevention & Chronic Conditions
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Author(s): Chris Wai Hang Lo , Yue Fei , Bernard Man Yung Cheung Added: 3 years ago

Prevention & Chronic Conditions
Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
Author(s): Muhammad Shahzeb Khan , Javed Butler Added: 4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Andrew JS Coats , Faiez Zannad , Stefan Anker , et al Added: 3 years ago
This roundtable eventincludes four leading heart failure specialists discussing recentdata related to SGLT2 inhibitors in reducing CV risk, HF hospitalisations andmortality and morbidity in HFrEF irrespective of T2DM. The panel also look at ongoing studies including those for HFpEF and CKD outcomes. View more

Heart Failure
AHA 21: Results From Rose Clinical Trial CETPi Lowers LDL-C in Patients Taking High Intensity Statins
Author(s): Stephen Nicholls Added: 2 years ago
In this video interview, Prof Stephen Nicholls (Victorian Heart Institute, Calyton, AU) shares the findings from the ROSE Clinical Trial. The placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluated the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy. Presented at AHA 2021, the study demonstrated that CETPi lowers LDL-C… View more

Heart Failure

Prevention & Chronic Conditions
Author(s): Thomas A Zelniker , Eugene Braunwald Added: 3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the… View more

Heart Failure
Author(s): Giuseppe Rosano , Cristiana Vitale , Petar M Seferovic Added: 3 years ago
Diabetes mellitus is highly prevalent amongst patients with heart failure, especially those with heart failure and preserved ejection fraction (HFpEF), and patients with the two conditions have a higher risk of mortality compared with patients without diabetes or heart failure.1–3 Diabetic patients have an increased risk of developing heart failure because of the abnormal cardiac handling of… View more

Heart Failure

Prevention & Chronic Conditions
AHA 23: 3 Trials That Will Change My Practice
Author(s): Purvi Parwani Added: 4 months ago
AHA 23 — Dr Purvi Parwani, cardiologist and multimodality imager, and director of the Women's Heart Clinic at Loma Linda University Health in the US, spotlights three game-changing late-breaking science trials from the AHA Scientific Sessions. Discover the trials anticipated to reshape clinical practices as Dr Parwani shares her insights.Trials discussed in detail include:POP-HT: Cardiac… View more

Standards & Guidelines

Prevention & Chronic Conditions
T1 and T2 Mapping in Uremic Cardiomyopathy: An Update
Author(s): Luca Arcari , Giovanni Camastra , Federica Ciolina , et al Added: 2 years ago

Imaging & Diagnostics